KR101107508B1 - 텔미사탄을 포함하는 고형 약제학적 제형 - Google Patents
텔미사탄을 포함하는 고형 약제학적 제형 Download PDFInfo
- Publication number
- KR101107508B1 KR101107508B1 KR1020057005123A KR20057005123A KR101107508B1 KR 101107508 B1 KR101107508 B1 KR 101107508B1 KR 1020057005123 A KR1020057005123 A KR 1020057005123A KR 20057005123 A KR20057005123 A KR 20057005123A KR 101107508 B1 KR101107508 B1 KR 101107508B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- telmisartan
- spray
- pharmaceutical composition
- tablet
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
가장 바람직한 비이온성 계변활성제는 폴록사머로부터 선택되고,
제형 | A | B |
텔미사탄 메글루민 폴록사머188 D-만니톨 결정성 셀룰로오스(Avicel PH101) 스테아르산마그네슘 |
40㎎ 40㎎ 8㎎ 81㎎ 30㎎ 1㎎ |
40㎎ 40㎎ 0㎎ 89㎎ 30㎎ 1㎎ |
총량 | 200㎎/캡슐 | 200㎎/캡슐 |
제형 | C | D | E | F | G |
텔미사탄 | 40.0㎎ | 40.0㎎ | 40.0㎎ | 40.0㎎ | 40.0㎎ |
메글루민 | 40.0㎎ | 40.0㎎ | 40.0㎎ | 40.0㎎ | 40.0㎎ |
폴록사머188 | 8.0㎎ | 8.0㎎ | 8.0㎎ | 8.0㎎ | 8.0㎎ |
D-만니톨 | 81.5㎎ | 80.6㎎ | - | 70.6㎎ | - |
에리트리톨 | - | - | 80.5㎎ | - | - |
소르비톨 | - | - | - | 10.0㎎ | - |
수크로오스 | - | - | - | - | 80.6㎎ |
결정성 셀룰로오스 | 30.0㎎ | - | - | - | - |
약한 무수 규산 | - | - | 0.1㎎ | - | - |
스테아르산마그네슘 | 0.5㎎ | 1.4㎎ | 1.4㎎ | 1.4㎎ | 1.4㎎ |
총량 | 200.0㎎ | 170.0㎎ | 170.0㎎ | 170.0㎎ | 170.0㎎ |
타정기 | Fette 3090 |
타정 속도 | 100,000(80,000 내지 120,000)정제수/시간 |
회전날 속도 | 약 30rpm |
압축력 | 7(5 내지 10)KN |
Claims (14)
- 염기성제와 텔미사탄의 몰 비 1:1 내지 10:1에 해당하는 염기성제(a),최종 조성물의 1 내지 20중량%에 해당하는 계면활성제 또는 유화제(b),수용성 희석제(c) 25 내지 70중량%, 및추가의 부형제 또는 보조제(d) 0 내지 20중량%를 포함하는 용해 매트릭스에 분산된 텔미사탄 3 내지 50중량%를 포함하고, 모든 구성 성분의 총량이 100중량%인 약제학적 조성물.
- 제1항에 있어서, 염기성제가 금속 수산화물이거나; 염기성 아미노산이거나; NaHCO3, KHCO3, Na2CO3, K2CO3, Na2HPO4, K2HPO4, 및 메글루민(N-메틸-D-글루카민)으로부터 선택되는 약제학적 조성물.
- 제1항에 있어서, 계면활성제 및 유화제가, 폴록사머 또는 플루로닉, 폴리에틸렌 글리콜, 폴리에틸렌 글리콜 모노스테아레이트, 폴리소르베이트, 나트륨 라우릴 설페이트, 폴리에톡시화 피마자유 및 수소화 피마자유로부터 선택되는 약제학적 조성물.
- 제1항에 있어서, 계면활성제 및 유화제가 평균 몰 중량이 2,000 내지 12,000인 폴록사머로부터 선택되는 약제학적 조성물.
- 제4항에 있어서, 폴록사머가 폴록사머 182LF, 폴록사머 331 및 폴록사머 188로부터 선택되는 약제학적 조성물.
- 제1항에 있어서, 수용성 희석제가 단당류; 올리고당; 및 당알코올인 에리트리톨, 소르비톨, 만니톨, 둘시톨, 리비톨 및 자일리톨로부터 선택되는 약제학적 조성물.
- 제1항에 있어서, 기타 부형제 또는 보조제가 결합제, 담체, 윤활제, 유동 조절제, 결정화 억제제, 가용화제 및 착색제로부터 선택되는 약제학적 조성물.
- 삭제
- 제1항 내지 제7항 중의 어느 한 항의 약제학적 조성물로부터 제조한, 캡슐 또는 정제 형태인 복용/섭취용의 고형 경구투여용 약제학적 제형.
- 제9항에 있어서, 단위 용량에 텔미사탄 10 내지 160㎎을 포함하는 약제학적 제형.
- 삭제
- 텔미사탄 3 내지 50중량%를, 염기성제와 텔미사탄의 몰 비 1:1 내지 10:1에 해당하는 염기성제(a) 및 비이온성 계면활성제 또는 유화제(b) 1 내지 20중량%와 함께 물, 또는 에탄올과 물의 혼합액에 용해시킴으로써 과립액을 수용액으로서 제조하는 단계(ⅰ),수용성 희석제 25 내지 70중량%를 건식 결합제 10 내지 20중량%와 함께 유동층 과립화기에 주입하여 예비-혼합을 수행하는 단계(ⅱ),과립화기 내에 있는 성분들에 분무하기 위한 과립액을 사용하여 유동층 과립화를 수행하는 단계(ⅲ),과립화 종료 후, 수득한 과립을 건조시키고, 스크리닝(screening)하는 단계(ⅳ),이렇게 수득한 과립을 추가의 부형제 또는 보조제와 블렌딩하여 최종 조성물을 제조하는 단계(v), 및이렇게 수득한 과립을 분쇄시켜 분말 조성물을 생성시키는 단계(vi)를 포함함을 특징으로 하고, 이때, 주어진 모든 백분율은 제조되는 최종 조성물을 기준으로 하는, 유동층 과립화 공정(A)을 이용한 제1항의 약제학적 조성물의 제조방법.
- 텔미사탄 3 내지 50중량%를, 염기성제와 텔미사탄의 몰 비 1:1 내지 10:1에 해당하는 염기성제(a) 및 비이온성 계면활성제 또는 유화제(b) 1 내지 20중량%와 함께 물, 또는 에탄올과 물의 혼합액에 용해시킴으로써 수성 분무액을 제조하는 단계(ⅰ),수성 분무액을 분무-건조시켜 분무-건조된 과립을 수득하는 단계(ⅱ),분무-건조된 과립을 수용성 희석제 25 내지 70중량%와 혼합하여 예비 혼합물을 수득하는 단계(ⅲ),예비 혼합물을 윤활제와 혼합하는 단계(ⅳ) 및단계(ⅰ) 내지 단계(ⅳ) 중의 어느 한 단계에서 추가의 부형제 또는 보조제를 첨가하는 단계(ⅴ)를 포함함을 특징으로 하고, 이때, 주어진 모든 백분율은 제조되는 최종 조성물을 기준으로 하는, 분무-건조 공정(B)을 이용한 제1항의 약제학적 조성물의 제조방법.
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10244681A DE10244681A1 (de) | 2002-09-24 | 2002-09-24 | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
DE10244681.4 | 2002-09-24 | ||
PCT/EP2003/010382 WO2004028505A1 (en) | 2002-09-24 | 2003-09-18 | Solid pharmaceutical formulations comprising telmisartan |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117025399A Division KR101188650B1 (ko) | 2002-09-24 | 2003-09-18 | 텔미사탄을 함유하는 제1 정제층과 이뇨제를 함유하는 제2 붕해성 정제층을 포함하는 이중층 약제학적 정제 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050053690A KR20050053690A (ko) | 2005-06-08 |
KR101107508B1 true KR101107508B1 (ko) | 2012-01-31 |
Family
ID=31984063
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057005123A KR101107508B1 (ko) | 2002-09-24 | 2003-09-18 | 텔미사탄을 포함하는 고형 약제학적 제형 |
KR1020117025399A KR101188650B1 (ko) | 2002-09-24 | 2003-09-18 | 텔미사탄을 함유하는 제1 정제층과 이뇨제를 함유하는 제2 붕해성 정제층을 포함하는 이중층 약제학적 정제 및 이의 제조방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020117025399A KR101188650B1 (ko) | 2002-09-24 | 2003-09-18 | 텔미사탄을 함유하는 제1 정제층과 이뇨제를 함유하는 제2 붕해성 정제층을 포함하는 이중층 약제학적 정제 및 이의 제조방법 |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP1545467B1 (ko) |
JP (1) | JP4606166B2 (ko) |
KR (2) | KR101107508B1 (ko) |
CN (2) | CN101785769A (ko) |
AR (2) | AR041370A1 (ko) |
AT (1) | ATE372765T1 (ko) |
AU (1) | AU2003270220B2 (ko) |
BR (1) | BR0314687A (ko) |
CA (1) | CA2499878C (ko) |
CY (1) | CY1107075T1 (ko) |
DE (2) | DE10244681A1 (ko) |
DK (1) | DK1545467T3 (ko) |
EA (1) | EA009237B1 (ko) |
EC (1) | ECSP055688A (ko) |
ES (1) | ES2294312T3 (ko) |
HR (1) | HRP20050280B1 (ko) |
IL (1) | IL167610A (ko) |
ME (1) | MEP46008A (ko) |
MX (1) | MXPA05003039A (ko) |
MY (1) | MY136524A (ko) |
NO (1) | NO334449B1 (ko) |
NZ (1) | NZ539522A (ko) |
PE (1) | PE20040418A1 (ko) |
PL (1) | PL206396B1 (ko) |
PT (1) | PT1545467E (ko) |
RS (1) | RS51756B (ko) |
SI (1) | SI1545467T1 (ko) |
TW (1) | TWI319319B (ko) |
UA (1) | UA81781C2 (ko) |
UY (1) | UY27995A1 (ko) |
WO (1) | WO2004028505A1 (ko) |
ZA (1) | ZA200501087B (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
PT1586310E (pt) * | 2004-04-15 | 2007-02-28 | Helm Ag | Processo para a preparação de adsorvatos de valsartan na forma de pó solto |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
MX2007004426A (es) | 2004-10-15 | 2007-06-14 | Teva Pharma | Procesos para preparar telmisartan. |
US20060293377A1 (en) * | 2004-11-03 | 2006-12-28 | Shlomit Wizel | Amorphous and polymorphic forms of telmisartan sodium |
UA89065C2 (ru) * | 2004-11-05 | 2009-12-25 | Бёрингэр Ингэльхайм Интэрнациональ Гмбх | Двухслойная таблетка, которая содержит телмисартан и амлодипин |
US9149433B2 (en) * | 2004-11-30 | 2015-10-06 | Basf Corporation | Method for formation of micro-prilled polymers |
CN100370984C (zh) * | 2005-03-11 | 2008-02-27 | 浙江泰利森药业有限公司 | 替米沙坦分散片及其制备方法 |
CA2623018A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of telmisartan |
US8637078B2 (en) * | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
CA2654890C (en) | 2006-06-16 | 2015-10-06 | Lek Pharmaceuticals D.D. | Pharmaceutical composition |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
FR2918277B1 (fr) * | 2007-07-06 | 2012-10-05 | Coretecholding | Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues |
EP2291177A2 (en) | 2008-05-05 | 2011-03-09 | Farmaprojects, S.A. | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
US9169238B2 (en) | 2008-07-31 | 2015-10-27 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
CZ301070B6 (cs) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablety |
DK2432452T3 (en) * | 2009-05-20 | 2016-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutically telmisartan drink solution |
EP2443094B1 (en) | 2009-06-19 | 2013-03-20 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
EP2448575A2 (en) | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
WO2011002423A2 (en) | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
JP2011136908A (ja) * | 2009-12-25 | 2011-07-14 | Kyowa Yakuhin Kogyo Kk | アンギオテンシンii受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンii受容体拮抗剤の保存安定性向上方法 |
CA2706292A1 (en) * | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
TWI564008B (zh) * | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | 難溶性藥物之溶解性改善製劑 |
CN102133189B (zh) * | 2011-03-18 | 2012-06-27 | 海南美兰史克制药有限公司 | 替米沙坦脂质体固体制剂 |
JP6081376B2 (ja) * | 2011-12-28 | 2017-02-15 | ニプロ株式会社 | アンギオテンシンii拮抗作用を有する化合物を含有する固形医薬組成物 |
EP2612658A1 (en) | 2012-01-05 | 2013-07-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide |
WO2014068507A1 (en) | 2012-11-02 | 2014-05-08 | Abbott Healthcare Pvt. Ltd. | Solid oral pharmaceutical compositions of telmisartan, essentially free of surfactants |
JP6379044B2 (ja) * | 2013-01-31 | 2018-08-22 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
JP6218664B2 (ja) * | 2013-04-04 | 2017-10-25 | 沢井製薬株式会社 | テルミサルタン含有錠剤 |
JP6344678B2 (ja) * | 2013-09-27 | 2018-06-20 | キョーリンリメディオ株式会社 | テルミサルタン含有製剤及びその製造方法 |
CN104688696B (zh) * | 2013-12-04 | 2017-12-19 | 长春海悦药业股份有限公司 | 一种含有坎地沙坦酯的药物组合物 |
JP6428340B2 (ja) * | 2014-05-23 | 2018-11-28 | ニプロ株式会社 | テルミサルタンを含む医薬組成物の造粒方法 |
JP6440294B2 (ja) * | 2014-07-01 | 2018-12-19 | 大原薬品工業株式会社 | テルミサルタン含有フィルムコーティング錠剤 |
EP2979691A1 (en) * | 2014-07-30 | 2016-02-03 | Boehringer Ingelheim International GmbH | Oral disintegrating tablet |
WO2016080357A1 (ja) * | 2014-11-19 | 2016-05-26 | ニプロ株式会社 | 口腔内崩壊錠の製造方法 |
JP5827428B1 (ja) * | 2015-01-15 | 2015-12-02 | 日新製薬株式会社 | テルミサルタン含有錠剤 |
CN104739833A (zh) * | 2015-02-16 | 2015-07-01 | 江苏欧信医药化工有限公司 | 含替米沙坦和瑞舒伐他汀钙的复方双层片剂及其制备方法 |
JP5956034B1 (ja) * | 2015-07-27 | 2016-07-20 | エルメッド エーザイ株式会社 | テルミサルタン含有医薬組成物 |
CN107982232A (zh) * | 2018-01-29 | 2018-05-04 | 威特(湖南)药业有限公司 | 替米沙坦片及其制备方法 |
CN109350604B (zh) * | 2018-11-20 | 2020-04-21 | 广州迈达康医药科技有限公司 | 一种替米沙坦肠溶片及其制备方法 |
CN110934848B (zh) * | 2019-12-20 | 2022-02-15 | 江西杏林白马药业股份有限公司 | 一种替米沙坦胶囊及其制备方法 |
CN111265488B (zh) * | 2020-03-18 | 2021-11-12 | 重庆康刻尔制药股份有限公司 | 一种替米沙坦片及其制备方法 |
CN112870174A (zh) * | 2021-02-08 | 2021-06-01 | 天方药业有限公司 | 一种替米沙坦片剂的制备方法 |
CN115245497A (zh) * | 2021-04-26 | 2022-10-28 | 武汉伯睿科医药科技有限公司 | 替米沙坦胶囊及其制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
FR2787330A1 (fr) * | 1998-12-18 | 2000-06-23 | Sanofi Sa | Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
AU1157500A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
JP2001139461A (ja) * | 1999-11-10 | 2001-05-22 | Ohta Pharmaceut Co Ltd | 速崩壊性錠剤 |
JP2001278812A (ja) * | 2000-03-27 | 2001-10-10 | Kyoto Pharmaceutical Industries Ltd | 錠剤用崩壊剤及びこれを用いた錠剤 |
EP2260833B1 (en) * | 2002-01-16 | 2012-11-21 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic |
-
2002
- 2002-09-24 DE DE10244681A patent/DE10244681A1/de not_active Withdrawn
-
2003
- 2003-09-18 ME MEP-460/08A patent/MEP46008A/xx unknown
- 2003-09-18 KR KR1020057005123A patent/KR101107508B1/ko active IP Right Grant
- 2003-09-18 EA EA200500405A patent/EA009237B1/ru not_active IP Right Cessation
- 2003-09-18 ES ES03750572T patent/ES2294312T3/es not_active Expired - Lifetime
- 2003-09-18 DK DK03750572T patent/DK1545467T3/da active
- 2003-09-18 AU AU2003270220A patent/AU2003270220B2/en not_active Ceased
- 2003-09-18 DE DE60316323T patent/DE60316323T2/de not_active Expired - Lifetime
- 2003-09-18 EP EP03750572A patent/EP1545467B1/en not_active Expired - Lifetime
- 2003-09-18 AT AT03750572T patent/ATE372765T1/de active
- 2003-09-18 MX MXPA05003039A patent/MXPA05003039A/es active IP Right Grant
- 2003-09-18 CN CN201010119310A patent/CN101785769A/zh active Pending
- 2003-09-18 WO PCT/EP2003/010382 patent/WO2004028505A1/en active IP Right Grant
- 2003-09-18 BR BR0314687-1A patent/BR0314687A/pt not_active Application Discontinuation
- 2003-09-18 RS YU20050239A patent/RS51756B/sr unknown
- 2003-09-18 CN CNA038226057A patent/CN1684665A/zh active Pending
- 2003-09-18 CA CA2499878A patent/CA2499878C/en not_active Expired - Fee Related
- 2003-09-18 JP JP2004538936A patent/JP4606166B2/ja not_active Expired - Lifetime
- 2003-09-18 NZ NZ539522A patent/NZ539522A/en not_active IP Right Cessation
- 2003-09-18 UA UAA200503742A patent/UA81781C2/uk unknown
- 2003-09-18 KR KR1020117025399A patent/KR101188650B1/ko active IP Right Grant
- 2003-09-18 PL PL374347A patent/PL206396B1/pl unknown
- 2003-09-18 PT PT03750572T patent/PT1545467E/pt unknown
- 2003-09-18 SI SI200331041T patent/SI1545467T1/sl unknown
- 2003-09-22 PE PE2003000967A patent/PE20040418A1/es not_active Application Discontinuation
- 2003-09-22 UY UY27995A patent/UY27995A1/es not_active Application Discontinuation
- 2003-09-23 TW TW092126213A patent/TWI319319B/zh not_active IP Right Cessation
- 2003-09-23 MY MYPI20033613A patent/MY136524A/en unknown
- 2003-09-24 AR ARP030103469A patent/AR041370A1/es not_active Application Discontinuation
-
2005
- 2005-02-07 ZA ZA200501087A patent/ZA200501087B/en unknown
- 2005-02-09 NO NO20050688A patent/NO334449B1/no not_active IP Right Cessation
- 2005-03-18 EC EC2005005688A patent/ECSP055688A/es unknown
- 2005-03-22 IL IL167610A patent/IL167610A/en not_active IP Right Cessation
- 2005-03-23 HR HRP20050280AA patent/HRP20050280B1/hr not_active IP Right Cessation
-
2007
- 2007-12-07 CY CY20071101558T patent/CY1107075T1/el unknown
-
2012
- 2012-07-19 AR ARP120102611A patent/AR087239A2/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
FR2787330A1 (fr) * | 1998-12-18 | 2000-06-23 | Sanofi Sa | Composition pharmaceutique contenant, en association, un antagoniste des recepteurs at1 de l'angiotensine ii et un immunosuppresseur pour la prevention ou le traitement des complications vasculaires du rejet de greffe |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101107508B1 (ko) | 텔미사탄을 포함하는 고형 약제학적 제형 | |
JP4181503B2 (ja) | テルミサルタンと利尿剤とを含有する二層医薬錠剤及びその製法 | |
US8637078B2 (en) | Bilayer tablet comprising telmisartan and diuretic | |
US8980870B2 (en) | Solid telmisartan pharmaceutical formulations | |
RU2465900C2 (ru) | Фармацевтические композиции, содержащие ирбесартан | |
WO1999020277A1 (fr) | Composition medicamenteuse a dissolution rapide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150105 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160104 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161230 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180105 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190107 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20200103 Year of fee payment: 9 |